Search

everythinglearnresearchcommunity

for

Search:↓

GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A person shared their hair transplant experience, mentioning complications like excessive bleeding and density anxiety, and is using finasteride and minoxidil chewables. They traveled to Turkey for the procedure, paid around $3800, and are considering Mexico for future treatments; nicotine use is a concern for their recovery.

The conversation is about a user making a homemade topical dutasteride solution to use alongside testosterone replacement therapy (TRT) and oral dutasteride. The user aims to reduce DHT locally at the testosterone injection site and on the scalp.

The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

CB-03-01 (Breezula) powder for hair loss. Users discuss its availability and seek feedback on its effectiveness.

The user is using a hair loss treatment regimen that includes applying various topical solutions and taking oral medication. They are mixing their topical treatments to save time but are concerned about the effectiveness of the treatments when combined and stored.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation is about using GHK-Cu, a copper peptide, for hair loss treatment. Users discuss their experiences, dosages, and additional benefits like improved skin and energy.

The conversation is about a user's comprehensive hair loss treatment plan, including finasteride, minoxidil, dermaroller, Nizoral shampoo, vitamin D, biotin, and zinc. The user describes their approach as a strategic battle against DHT, with finasteride as the main treatment.

The conversation humorously discusses diverting DHT from head to body hair and explores the idea of transplanting body hair to the scalp. It also mentions the potential for treatments to prevent DHT from affecting hair follicles.

The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.

The user started using 1mg finasteride and Regaine foam post-hair transplant, noticing significant hair growth at three months. They experienced testicular cramps as a side effect but no other issues, and are considering microneedling for further improvement.

GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

A user expressed satisfaction with a hair and beard transplant at HairofIstanbul using 3200 grafts and PRP, achieving natural-looking results without finasteride or minoxidil. The transformation was praised, though some noted the beard line appeared artificial.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

Body hair transplants may look better if kept very short. People with limited donor regions or waiting for Verteporfin or FAK Inhibitors could consider this option.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.